StockData
Summit Therapeutics Inc. logo

Summit Therapeutics Inc. (SMMT) stock

SMMTNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 6/30
$10.67−1.15 (-9.73%)

Close on Nov 17, 2026Market cap $8.51BP/E –Yield –

Summit Therapeutics operating margin

Operating margin is operating income as a percentage of revenue.

Summit Therapeutics's operating margin for the twelve months ending Jun 30, 2023 was -268266.8%. For fiscal 2022 it was -10225.4%, against -4764.3% the year before.

Annual operating margin

PeriodPeriod endValueChange (pts)
FY2022Dec 31, 2022-10225.4%−5461.1
FY2021Dec 31, 2021-4764.3%−4773.7
FY2019Jan 31, 20199.4%–

Quarterly operating margin

Change is against the same quarter a year earlier.

Periods
PeriodPeriod endValueChange (pts)
Q3 FY2022CQ3 2022Sep 30, 2022-7700.0%−6211.4
Q2 FY2022CQ2 2022Jun 30, 2022-5400.9%+36230.7
Q1 FY2022CQ1 2022Mar 31, 2022-8863.2%−49.1
Q4 FY2021CQ4 2021Dec 31, 2021-10377.3%–
Q3 FY2021CQ3 2021Sep 30, 2021-1488.6%–
Q2 FY2021CQ2 2021Jun 30, 2021-41631.6%–
Q1 FY2021CQ1 2021Mar 31, 2021-8814.1%–

More Summit Therapeutics figures

See a number that looks wrong?